BIO's Letter to the Senate Committee on Judiciary Regarding Deficiencies at the USPTO
BIO President and CEO James C. Greenwood details deficiencies at the USPTO that are undermining longstanding and carefully-balanced procedures governing market entry and patent dispute resolution under the highly successful Hatch-Waxman Act.